Countries China

Immunofoco Achieves Historic Dual IND Approval for Groundbreaking EpCAM CAR-T Therapy

  EpCAM, known for its presence in circulating tumor cells (CTCs) and high expression in primary and metastatic lesions of gastrointestinal tumors, r...

 February 26, 2024 | News

Hox Therapeutics and Vernalis Enter Collaboration to Advance Oncology Drug Discovery

Hox Therapeutics Ltd, a pioneering biotechnology company dedicated to developing targeted cancer therapies, and Vernalis (R&D) Ltd, a renowned subsidia...

 February 22, 2024 | News

Innovent's IBI311 Clears Phase 3 Hurdle for Thyroid Eye Disease with Promising Results

The trial also successfully met its key secondary endpoints, including the overall response rate, the percentage of subjects achieving a clinical activity ...

 February 20, 2024 | News

Biocytogen and Gilead Forge Landmark Collaboration to Harness Fully Human Antibody Library for Therapeutic Innovations

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a leading biotechnology company,  announced a significant coll...

 February 20, 2024 | News

Jacobio Gains China CDE Approval for Phase III SHP2 and KRAS G12C Inhibitor Trial

This approved study in China is a randomized active controlled phase III trial design to evaluate the efficacy and safety of JAB-3312 in combinat...

 February 19, 2024 | News

Brii Biosciences Secures Intellectual Property Rights for HBV Treatment from VBI Vaccines

Brii Biosciences Limited ("Brii Bio"), a leader in developing innovative treatments for diseases with significant unmet needs, has announced a strategic ac...

 February 14, 2024 | News

Cathay Biotech and 3P.COM Forge Groundbreaking Joint Venture to Propel Sustainable Composite Innovations

In a strategic move towards sustainable innovation, Cathay Biotech Inc. of China and 3P.COM Co. Limited of South Korea have signed a landmark joint venture...

 February 09, 2024 | News

Innovent Biologics Advances Novel Weight Management Drug Mazdutide with NDA Acceptance in China

  This groundbreaking achievement marks mazdutide as the first GLP-1R/GCGR dual agonist to successfully complete Phase 3 trials in support of an NDA ...

 February 08, 2024 | Regulatory

Nordic Bioscience Partners with Roche for PRO-C3 Biomarker in China

The PRO-C3 biomarker is relevant for drug development in particularly chronic diseases with a fibrotic component e.g., non-alcoholic steatohepatitis (NASH,...

 February 06, 2024 | News

NouvNeu001 Marks Milestone in iRegene's c Trial with Successful First Patient Dosing

It is reported that the multicenter, open-label clinical trial (Phase I/II) is meticulously crafted to systematically evaluate the safety, tolerability, an...

 February 06, 2024 | News

Sirius Therapeutics Begins Phase 1 Trial for Long-Acting Factor XI siRNA Anticoagulant

"This study is based on in vivo studies that have demonstrated a nearly 100% reduction in FXI levels for up to 6 months without bleeding events a...

 February 04, 2024 | News

RemeGen Spotlights Three Major Advances in Global Cancer Battle, Closing Care Gap

Dr. Jianmin Fang, CEO of RemeGen, commented, "Cancer is the common enemy of mankind, and at RemeGen we feel a strong sense of responsibility and missi...

 February 02, 2024 | News

WuXi XDC Partners with Multitude and HySlink for Accelerated ADC Discovery and Development

WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. As WuXi XDC's strategic partner, Multitude Therapeu...

 January 31, 2024 | News

Ractigen Therapeutics Partners with Utrecht Medical Center for saRNA Innovation in Neurodevelopmental Disorders

Professor Bobby Koeleman, Group Leader at the Department of Genetics within the Center for Molecular Medicine at Utrecht University, will le...

 January 30, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close